While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of our products; CytoDyn, our collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.We are also subject to additional risks and uncertainties, including risks associated with the actions of our corporate, academic and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; and risks that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity. There are also substantial risks arising out of our need to raise additional capital to develop our products and satisfy our financial obligations; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; the highly competitive nature of our industry; and other factors set forth in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.
CytoDyn Inc. ("CytoDyn") (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that it will be presenting an update on the company’s technology during the 31st Annual J.P. Morgan Healthcare Conference on January 9, 2013 at 3:15 PM PT. More information regarding the conference can be found at http://www.ebdgroup.com/bts/index.php. “The Biotech Partnering Showcase held in conjunction with the J.P. Morgan meeting is an excellent venue for CytoDyn to feature the Company’s exciting development initiatives, including development of our Phase II PRO 140 antiretroviral humanized monoclonal antibody product, with many of the industry’s leading participants.” said Dr. Pourhassan, CytoDyn’s CEO and President. “We are looking forward to the opportunity to present a concise and up-to-date review of the company’s progress over the last year as well as our acquisition of our new anti-HIV program PRO 140.” Richard Trauger, CSO, will present an overview of the company’s programs on Wednesday January 9 th at 3:15 pm. The presentation can be viewed live at the specified time online at: http://www.media-server.com/m/p/49iya8t6. This presentation will be followed by a breakout Q&A open to the conference participants. The webcast will be available approximately one hour after the webcast presentation ends and is accessible for 90 days. The Company CytoDyn is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. Its proprietary drug candidate PRO 140 is a humanized monoclonal antibody which has demonstrated the ability to block the entry of HIV virus into human white blood cells by binding to a cell surface protein known as CCR5. PRO 140 has completed Phase I and Phase IIa human clinical trials. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with the Human Immunodeficiency Virus (“HIV”). In addition, CytoDyn is seeking partners for the development of another proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus (“FIV”), a retroviral infection in cats. CytoDyn recently filed for a provisional patent for the use of these anti-FIV antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV. For more information please go to www.cytodyn.com. Forward-Looking Statements This press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn’s intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond CytoDyn’s control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words "believe," "estimate," "expect," "intend," "attempt," "anticipate," "foresee," "plan," and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. CytoDyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information.